Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival

Fig. 2

 H&E and immunohistochemistry (IHC) staining for Ki-67 expression in breast cancer tissues and positive control. a). H&E staining of low Ki-67 expression in breast cancer tissue. b). H&E staining of high Ki-67 expression in breast cancer tissue. c-k). IHC staining of Ki-67 manifested in the nucleus in: c). Positive control tissue (colon tissue). d). Luminal A breast cancer subtype (low expression level ≤ 22%). e). Luminal A breast cancer subtype (high expression level > 22%). f). HER2-enriched breast cancer subtype (low expression level ≤ 22%). g). HER2-enriched breast cancer subtype (high expression level > 22%). h). Triple positive breast cancer subtype (low expression level ≤ 22%). i). Triple positive breast cancer subtype (high expression level > 22%). j). Triple negative breast cancer subtype (low expression level ≤ 22%). k). Triple negative breast cancer subtype (high expression level > 22%). Arrows indicate the positively stained cells. Scale bar: 400 × (40X objective lens x 10X ocular lens = 20 μm).

Back to article page